Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)

11/23/2021 | 05:12pm EST

Item 8.01. Other Events.


On November 23, 2021, the Company issued a press release announcing the launch
of the STAR Offering. A copy of this press release is attached hereto as Exhibit
99.1, and is incorporated herein by reference.

On November 23, 2021, the Company issued a press release announcing that the
European Commission (EC) approved BRUKINSA® (zanubrutinib) for the treatment of
adult patients with Waldenström's macroglobulinemia (WM) who have received at
least one prior therapy or for the first-line treatment of patients unsuitable
for chemo-immunotherapy. The approval is applicable to all 27 European Union
(EU) member states, plus Iceland and Norway. A copy of this press release is
attached hereto as Exhibit 99.2, and is incorporated herein by reference.

On November 23, 2021, the Company announced that it has purchased a 42-acre site
at the Princeton West Innovation Campus in Hopewell, N.J. to house a new
state-of-the-art manufacturing campus and clinical R&D center. As a key part of
BeiGene's continued growth, the company is investing in U.S. manufacturing to
further expand and diversify its global supply chain and build new manufacturing
capabilities for its deep pipeline of biologic and drug candidates. A copy of
this press release is attached hereto as Exhibit 99.3, and is incorporated
herein by reference.

On November 22, 2021, the Company announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor internally developed by BeiGene scientists. A copy of this press release is attached hereto as Exhibit 99.4, and is incorporated herein by reference.


On November 19, 2021, the China National Medical Products Administration
approved POBEVCY® (a biosimilar to bevacizumab injection) for the treatment of
patients with advanced, metastatic or recurrent non-small cell lung cancer
(NSCLC) and metastatic colorectal cancer. BeiGene has rights to develop,
manufacture, and commercialize POBEVCY® in China (including Hong Kong, Macao and
Taiwan) under a collaboration agreement with Bio-Thera Solutions, Ltd. entered
in August 2020.


--------------------------------------------------------------------------------

Forward-Looking Statements


This Current Report on Form 8-K contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and other
securities laws, including statements regarding the Proposed Issue of RMB Shares
under the general mandate to be listed on the STAR Market. Actual results may
differ materially from those indicated in the forward-looking statements as a
result of various important factors, including the possibility that the
conditions, including market conditions and customary closing conditions related
to the STAR Offering, will not be met and that BeiGene will be unable to
consummate the Proposed Issue of RMB Shares; the possibility that BeiGene will
not realize the expected benefits of the transaction; the possibility that the
final financial performance data will be different from the preliminary data;
BeiGene's ability to demonstrate the efficacy and safety of its drug candidates;
the clinical results for its drug candidates, which may not support further
development or marketing approval; actions of regulatory agencies, which may
affect the initiation, timing and progress of clinical trials and marketing
approval; BeiGene's ability to achieve commercial success for its marketed
medicines and drug candidates, if approved; BeiGene's ability to obtain and
maintain protection of intellectual property for its medicines and technology;
BeiGene's reliance on third parties to conduct drug development, manufacturing
and other services; BeiGene's limited experience in obtaining regulatory
approvals and commercializing pharmaceutical products and its ability to obtain
additional funding for operations and to complete the development and
commercialization of its drug candidates and achieve and maintain profitability;
the impact of the COVID-19 pandemic on the BeiGene's clinical development,
regulatory, commercial, and other operations, as well as those risks more fully
discussed in the section entitled "Risk Factors" in BeiGene's most recent
quarterly report on Form 10-Q as well as discussions of potential risks,
uncertainties, and other important factors in BeiGene's subsequent filings with
the U.S. Securities and Exchange Commission. All information in this Current
Report is as of the date of this Current Report, and BeiGene undertakes no duty
to update such information unless required by law.

The Proposed Issue of RMB Shares under the general mandate is subject to, among
other things, market conditions and customary closing conditions related to the
STAR Offering, and thus may or may not proceed. Shareholders and potential
investors of the Company should be aware that there is no assurance that the
Proposed Issue of RMB Shares will complete or as to when it may complete.
Shareholders and potential investors of the Company should exercise caution when
dealing in the securities of the Company.

Further announcement(s) or filings will be made by the Company in accordance
with the applicable laws and regulations on any material updates and progress in
connection with the Proposed Issue of RMB Shares as and when appropriate. This
announcement is for information purposes only and does not constitute any
invitation or offer to acquire, purchase or subscribe for the securities of the
Company.


Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

   Exhibit No.            Description

       99.1               Press Release titled "BeiGene Launches Proposed

Initial Public Offering on the STAR

                          Market in China", issued by BeiGene, Ltd. on 

November 23, 2021.

       99.2               Press Release titled "BeiGene Announces Approval

of BRUKINSA® (zanubrutinib) in the

                          European Union for Treatment of Adults with 

Waldenström's Macroglobulinemia", issued

                          by BeiGene, Ltd. on November 23, 2021.

       99.3               Press Release titled "BeiGene Closes on Property

for New U.S. Manufacturing and

                          Clinical R&D Center", issued by BeiGene, Ltd. on 

November 23, 2021.


       99.4               Press Release titled "BeiGene Initiates 

First-in-Human Phase 1 Clinical Trial of

                          Investigational TYK2 Inhibitor BGB-23339", issued 

by BeiGene, Ltd. on November 22,

                          2021.

       104                The cover page from this Current Report on Form

8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about BEIGENE, LTD.
01/25BEIGENE : Announces Acceptance of a Supplemental New Drug Application in China for BRUKINS..
PU
01/25BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/25Immix Biopharma Sees Positive Data for Pancreatic Cancer Treatment in Mouse Trial
DJ
01/25BeiGene Says Global Phase 3 Study of Gastric Cancer Treatment Yields Positive Interim R..
MT
01/24BeiGene's Tislelizumab Boosts Overall Survival In Phase 3 Gastric Cancer Trial
MT
01/24BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination w..
BU
01/24BeiGene, Ltd. Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combina..
CI
01/21BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKIN..
AQ
01/20Health Care Stocks Higher Ahead of Thursday's Close
MT
01/20BeiGene Says China's Medical Products Regulator Accepts Supplemental NDA for Blood Cell..
MT
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations